SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB : CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company developing novel ...
SOUTH SAN FRANCISCO, Calif, Nov. 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) shares are racing higher Thursday after the company announced the publication of preclinical research on the use of its clinical candidate CER-1236 to ...
Study will advance into expanded patient populations with myelodysplastic syndrome (MDS) and myelofibrosis (MF) ...
CERo Therapeutics Holdings, Inc. has announced the issuance of additional shares of its Series D Preferred Stock to institutional investors, following a previous agreement worth up to $8 million. This ...
Cero Therapeutics Holdings, Inc. (NASDAQ:CERO) announced on Tuesday that it has entered into a new stock purchase agreement with an institutional investor, allowing the company to issue and sell up to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results